Highlight
- In a large randomized trial comparing aspirin, warfarin, and rivaroxaban for VTE prevention after hip/knee arthroplasty, no agent was conclusively superior in preventing death or symptomatic venous thromboembolism (VTE) within six months.
- Aspirin did not meet the criteria for noninferiority compared with rivaroxaban or warfarin regarding efficacy; likewise, rivaroxaban and warfarin were not noninferior to aspirin in safety outcomes.
- The absolute event rates for efficacy and safety outcomes were low across all treatment groups, highlighting the overall effectiveness of all three regimens in contemporary practice.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
